; (C) in the case of antibiotics manufactured under this section, an assessment from the Centers for Disease Control and Prevention and the Food and Drug Administration on the impact of the manufacturing of antibiotics on antimicrobial resistance; (D) an accounting of funds received from the sale of all medications for which manufacturing has been authorized under this section and the use of such funds; (E) an analysis of how the public manufacture of drugs meeting the conditions described in paragraph (5) would impact, or has already impacted, competition, access to such drugs, the costs of such drugs, the costs of prescription drugs to Federal and State health programs, and public health; and (F) a description of the challenges faced by the Office in carrying out its duties under paragraph (4). (b) Submission of applications For each applicable drug that the Office determines should be manufactured, as provided for under this section, the Office shall— (1) submit an application under section 505(b)(2), 505(j), or 515 of the Federal Food, Drug, and Cosmetic Act or section 351(a) or 351(k) of this Act or submit a notification under section 510(k) of the Federal Food, Drug, and Cosmetic Act (or enter into a contract with another entity to submit such an application); (2) request an emergency use authorization of the product, as appropriate, under section 564 of the Federal Food, Drug, and Cosmetic Act (or enter into a contract with another entity to submit an application for such use)